HER2 aberrations in cancer: Implications for therapy.
United States. In Cancer Treat Rev, 12 Apr 2014
UNLABELLED: Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently approved for breast, gastric, and gastroesophageal cancers overexpressing the HER2 protein or amplified for the HER2 gene, HER2 aberrations (gene amplification, gene mutations, and protein overexpression) are reported in other diverse malignancies.
Epiregulin: Roles in normal physiology and cancer.
Auburn, United States. In Semin Cell Dev Biol, 11 Apr 2014
Epiregulin binds to the EGF receptor (EGFR/ErbB1) and ErbB4 (HER4) and can stimulate signaling of ErbB2 (HER2/Neu) and ErbB3 (HER3) through ligand-induced heterodimerization with a cognate receptor.
Met in lung cancer.
Richmond, United States. In Cancer Biol Ther, 11 Apr 2014
(1) Thus expression of mutant active EGFR but in general not wild type EGFR predisposes NSCLC cells to inhibitors of EGFR/ErbB2.
Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer.
Modena, Italy. In J Clin Oncol, 03 Apr 2014
PURPOSE: This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/human epidermal growth factor receptor 2 (HER2) -negative operable breast cancer.
Targeted therapy in HER2-positive breast cancer.
More papers using
Jinan, China. In Biomed Rep, Jul 2013
An important molecular determinant of therapy is the human epidermal growth factor receptor 2 (HER2) positivity of the tumor, which has been identified in 20-25% of breast cancers and is a prognostic marker of poor outcome.
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
In PLoS ONE, 2009
... Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, Ventana Medical Systems). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
In Breast Cancer Research : BCR, 2008
... (SP1 antibody, Neomarkers, Fremont, CA, USA), PR (PgR 636 antibody, Dako, Carpinteria, CA, USA) and HER2 (A085 antibody, Dako). A case of primary small cell carcinoma of the breast
In Pathology Research International, 2006
... antibodies were used: estrogen receptor (Novocastra, clone 6F11, 1 : 100), progesterone receptor (Novocastra, clone 16, 1 : 100), c-erbB-2 oncoprotein (Dako, HER-2), mammoglobin (Dako, clone ... The annexins
In Breast Cancer Research : BCR, 2003
... HER2/neu immunohistochemistryDako, polyclonal ... Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis
In Pathology Research International, 2002
... hours in a humidity chamber using the following dilutions: p53 (clone DO-7, titer 1 : 50, Dako, Denmark), HER-2/neu (titer 1 : 50, Dako, Denmark), ER (clone 1D5, ...